CPMV — Mosaic Immunoengineering Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Mosaic Immunoengineering, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 3.5 | 2.63 | 1.4 | 0.88 | 0.616 |
| Operating Profit | -3.5 | -2.63 | -1.4 | -0.88 | -0.616 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.68 | -2.38 | -1.01 | -0.92 | -0.685 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.68 | -2.38 | -1.01 | -0.922 | -0.688 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.68 | -2.38 | -1.01 | -0.922 | -0.688 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.68 | -2.38 | -1.01 | -0.922 | -0.688 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.549 | -0.329 | -0.139 | -0.127 | -0.095 |